Arrhythmias & electrophysiologyMeta-analysis

Left Atrial Appendage Occlusion vs Direct Oral Anticoagulants for Atrial Fibrillation

JACC AdvPublished

  • network meta-analyses
  • randomized controlled trials
  • indirect comparisons
  • MEDLINE and CENTRAL

Authors' conclusion

LAAO devices did not demonstrate statistical superiority over DOACs in reducing thromboembolic events and major bleeding. Further trials are warranted to define patients for whom LAAO may offer the most significant benefit, such as those with high bleeding risk (CRD420251237886).

Study context

Population
Patients with atrial fibrillationpatients from 11 randomized controlled trials, of whom 5,735 underwent left atrial appendage occlusion (LAAO)
Participants
67,693 patients
Comparison
LAAO vs DOAC
  • LAAOn = 5,735
Outcome
Composite of:
  • Stroke
  • Systemic embolism
  • Cardiovascular death

Pooled result

As reported in the abstract

Hazard ratio

1.02

95% CI 0.88–1.19

LAAO vs DOACs
HR 1.02 (95% CI 0.88–1.19)

Further pooled results

Primary outcome and major bleeding, 4-arm network meta-analysis

Amulet and Watchman associated with similar risks of the primary outcome, comparable to those of direct oral anticoagulants (DOACs), as well as the risk of major bleeding

Safety

OutcomeHR (95% CI)
Major bleeding · I2 = 70.5%; three-arm network meta-analysis · statistically similar risks0.98 (0.78–1.23)

Original publication

Left Atrial Appendage Occlusion vs Direct Oral Anticoagulants for Atrial Fibrillation. JACC Adv. Published 23 September 2026. doi:10.1016/j.jacadv.2026.103269

Summarised from the published abstract; every number is checked against it